<DOC>
	<DOCNO>NCT00003710</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness irinotecan plus mitomycin treating patient advance solid tumor persistent recurrent .</brief_summary>
	<brief_title>Irinotecan Plus Mitomycin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose mitomycin administer irinotecan patient advance solid tumor . II . Determine whether pharmacokinetic profile irinotecan alter prior administration mitomycin patient population . III . Determine effect irinotecan mitomycin expression DT-Diaphorase Topo I gene . IV . Determine preliminary antitumor activity regimen patient . OUTLINE : This dose escalation study . Patients receive mitomycin IV 20 30 minute day 1 irinotecan IV 90 minute day 2 , 8 , 15 , 22 , follow 2 week rest begin day 29 . Treatment continue every 6 week absence disease progression unacceptable toxicity . Cohorts 3 6 patient receive escalate dos mitomycin irinotecan maximum tolerate dose ( MTD ) reach . The MTD define dose 1 6 patient experience dose limit toxicity . Patients follow 1 month . PROJECTED ACCRUAL : Up 30 patient accrue study .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor standard therapy exist persistent recurrent follow prior therapy Measurable evaluable disease No hematologic malignancy ( e.g. , leukemia lymphoma ) No know brain leptomeningeal disease ( unless lesion irradiate , currently untreated corticosteroid , clinical symptom ) PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Karnofsky 70100 % Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin great 9 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) AST ALT less 3 time ULN Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Calcium great 12 mg/dL Cardiovascular : No myocardial infarction within 6 month No congestive heart failure require therapy No unstable angina Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No concurrent severe disease No psychiatric disorder No history seizure disorder No uncontrolled diabetes ( blood sugar great 200 mg/dL ) PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover Chemotherapy : At least 4 week since prior chemotherapy recover No prior mitomycin , irinotecan , nitrosoureas No 6 course chemotherapy contain alkylating agent No 4 course carboplatin Endocrine therapy : At least 4 week since prior endocrine therapy recover Radiotherapy : At least 4 week since prior radiotherapy recover No prior radiotherapy 20 % bone marrow No prior whole pelvis radiotherapy Surgery : Not specify Other : No concurrent phenytoin , phenobarbital , valproic acid , antiepileptic prophylaxis No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>